🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

AstraZeneca admits Covishield jab raises TTS risk. Should you be worried?

Published 30-04-2024, 09:30 pm
AstraZeneca admits Covishield jab raises TTS risk. Should you be worried?
AZN
-
AZN
-

New Delhi, April 30 (IANS) Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca’s Covid vaccine, and the risks far outweigh the benefits of the jab, said doctors here on Tuesday. This comes after reports said that AstraZeneca has for the first time accepted in court documents that its vaccine, developed in partnership with Oxford University, can raise the risk of a rare and serious blood clot.

The Oxford-AstraZeneca Covid vaccine, sold as Covishield in India and Vaxzevria in Europe is a viral vector vaccine developed using the modified chimpanzee adenovirus ChAdOx1.

Covishield manufactured and marketed in India in partnership with Serum Institute of India (SII), was widely administered in the country -- to almost 90 per cent of the Indian population.

“Thrombotic Thrombocytopenic Syndrome (TTS) is one of the rare but very serious adverse effects that has happened as part of Vaccine-induced Immune Thrombotic Thrombocytopenic Purpura (VITTP). The incidence has been as low as one in 50,000 (0.002 per cent), but in a huge population, the number becomes sizeable,” infectious disease expert Dr. Ishwar Gilada, told IANS.

“TTS is a very rare condition resulting from an abnormal immune response. Although it has several causes, it has also been linked with adenovirus vector vaccines and the WHO published a report on May 27, 2021 about it,” Dr Rajeev Jayadevan, co-chairman of the Indian Medical Association’s National Covid-19 Task Force, told IANS.

What is the case? The British-Swedish multinational pharmaceutical company has admitted for the first time in the UK court documents that its Covid vaccine can cause a rare blood clot risk, the Telegraph reported.

About 51 cases have been lodged in the UK High Court against the pharmaceutical giant over claims that its Covid vaccine caused death and serious injury.

The victims and grieving relatives have sought damages, estimated to be worth up to 100 million pounds, the report said.

Although AstraZeneca is contesting the claims “it has accepted, in a legal document submitted to the High Court in February that its Covid vaccine ‘can, in very rare cases, cause TTS’”, the report said.

TTS causes people to have blood clots and a low blood platelet count.

AstraZeneca’s Covid vaccine and link to TTS? In India, almost 90 per cent of people who received Covid vaccine, received the AstraZeneca vaccine which in India is called Covishield. It is made from a harmless cold virus, which is from chimpanzees and it is called adenovirus.

“Once this virus is genetically modified or engineered to match the SARS-CoV-2, a causative organism for Covid-19, this works on a spike protein. So, the vaccine is incorporated with the S spike protein genetic sequence,” said Dr. Ishwar, Secretary General People's Health Organisation-India, Mumbai.

Explaining the mechanism of potential TTS risk, he said that the vaccine is injected in the arm which is in the deltoid muscle. However, “sometimes instead of just getting into muscles, it also enters the bloodstream. Once it enters the bloodstream, the adenovirus in the vaccines acts like a magnet, with a special affinity to a type of protein in the blood called platelet factor 4 (PF4),” the doctor said.

“While PF4 is normally used by the body to promote coagulation in blood, in rare instances, the body's immune system confuses it as a foreign body or foreign invader and then releases antibodies to attack it -- called mistaken identity.

“It is theorised that such antibodies then react and clump together with PF4, forming the blood clots that have become so heavily linked with the vaccine. Such clots in the brain and heart can cause disastrous adverse effects,” the doctor said.

Should all Covishield vaccine takers be worried?

“No, we need not because it has happened to a very few people,” Dr. Ishwar said.

“The difficulty is to distinguish between the complications that are caused by Covid itself or long-Covid or the vaccine. That remains debatable and indistinguishable for the scientific community as also the legal fraternity,” he added.

Importantly, Dr. Rajeev said, “People who are vaccinated have an overall lower risk of death from Covid as well as complications such as post-Covid heart attacks and strokes afterward”.

“Although there are extremely rare serious side effects for vaccines, the benefits far outweigh the risks. Covid vaccines have prevented hundreds of thousands of people from dying. For example, in the US, 232,000-318,000 people have died from Covid, due to refusal to vaccinate from disproportionate fear of vaccination,” he added.

--IANS

rvt/rad

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.